Rashi Srivastava
Head of CMC Regulatory Affairs, Cell & Gene Therapies,
Astra Zeneca
Rashi Srivastava is a seasoned Associate Director in CMC Regulatory Affairs, specializing in cell and gene therapies. With a strong track record in navigating the complexities of Chemistry, Manufacturing, and Controls (CMC) processes, she collaborates closely with leading biopharma companies—evidenced by her recent focus on roles at AstraZeneca.
Based in the U.S. regulatory ecosystem, Rashi leverages her expertise to support end-to-end development of advanced biologics—from pre-IND planning through to commercial approvals. She brings a strategic vision for optimizing regulatory pathways, ensuring robust documentation, and aligning cross-functional teams including clinical, manufacturing, and regulatory science.